Phathom Pharmaceuticals Inc., a biopharmaceutical company focusing on gastrointestinal disease treatments, has announced the approval of new inducement awards for Jonathan Bentley, who has been appointed as Senior Vice President, Head of Sales. On May 1, 2025, the company's Board of Directors granted Bentley a non-qualified stock option to purchase 79,365 shares of common stock, with 25% vesting on May 1, 2026, and the rest vesting in 36 equal monthly installments. Additionally, Bentley received two restricted stock unit awards: 57,143 units vesting in three equal annual installments and 50,000 units vesting in two equal installments. These awards are part of the 2025 Employment Inducement Incentive Award Plan and are contingent on Bentley's continued service with the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。